Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915246 · ClinicalTrials.gov registry record · Phase 2
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
A Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by VIVUS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 4
- Study locations
NCT06915246: Recruiting Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by VIVUS.
NCT06915246 is a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by VIVUS. The registered enrollment target is 49 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915246, a Phase 2 study of Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by VIVUS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 4
- Study locations
Study Summary
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Conditions Studied
Interventions
- DRUG VI-0609
- DRUG BiCNU
Study Locations (4)
Arizona
- City of Hope Phoenix - Goodyear
California
- City of Hope National Medical Center - Duarte
Georgia
- City of Hope Atlanta - Newnan
Illinois
- City of Hope Chicago - Zion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What NCT06915246 shows while recruiting
NCT06915246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which VI-0609 is the first listed.
NCT06915246 reports a single indexed study location in Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06915246 about?
NCT06915246 is a clinical study titled "A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma". A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
What is the current status of trial NCT06915246?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2025-03-12. Estimated completion is 2026-04-30.
What conditions does trial NCT06915246 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT06915246?
The interventions under investigation include: VI-0609 (DRUG), BiCNU (DRUG).
Who is sponsoring clinical trial NCT06915246?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915246 being conducted?
This trial has 4 study locations across Arizona, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06915246's enrollment target sits among peer trials
49 156th of 299 higher than 144 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI